Endogena Therapeutics unlocks regenerative potential with FDA-approved AMD treatment
Endogena Therapeutics - 24-Oct-2023Company's EA 2351 paves the way for potential vision restoration in patients
Matthias Steger
Biotech Entrepreneur and co-founder and Chief Executive Officer at Endogena Therapeutics
Matthias has more than 20 years pharma / biotech experience and is the co-founder of Endogena Therapeutics. As former global head of research and technology partnering at Roche, Matthias set up and managed > 50 collaborations and acquisitions for novel drug modalities, drug discovery technologies and enabling technologies. He also established Roche’s stem cell research programme. An entrepreneur at heart, Matthias set up a pioneering orphan G-protein coupled receptor (GPCR) drug discovery company, which resulted in a successful acquisition. He gained financial experience as an investment banking analyst at Kepler Equities.
Visit website: https://rejuveron.com/en/who-we-are#people
See also: 
Rejuveron
- Company that develops and invests in drugs and technologies which prolong human lifespan.
Details last updated 20-Nov-2021
Matthias Steger is also referenced in the following:
Longevity Leaders World Congress 2022
26-Feb-2022 to 27-Feb-2022
Event for leaders in longevity science, technology, business and finance organized by Longevity Leaders (LSX)
Rejuveron Age Better Live Longer Symposium
10-May-2022
Symposium about healthy living organized by Rejuveron (FREE)
Matthias Steger News
FDA grants Endogena's primary program for EA-2353 suspension targeting retinitis pigmentosa
Biospace - 13-May-2021Endogena’s photoreceptor regeneration approach offers new treatment paradigm in retinitis pigmentosa
